$0.88
-0.03 (-3.04%)
Open$0.90
Previous Close$0.91
Day High$0.90
Day Low$0.87
52W High$4.35
52W Low$0.71
Volume—
Avg Volume301.0K
Market Cap23.40M
P/E Ratio—
EPS$-3.33
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,311.5% upside
Current
$0.88
$0.88
Target
$12.42
$12.42
$7.12
$12.42 avg
$14.14
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 65.86M | 48.26M | 10.25M |
| Net Income | -70,321,353 | -46,375,919 | 2.27M |
| Profit Margin | -106.8% | -101.4% | 22.1% |
| EBITDA | -60,985,413 | -42,453,390 | 3.06M |
| Free Cash Flow | — | — | 1.07M |
| Rev Growth | +36.5% | +36.5% | +24.9% |
| Debt/Equity | 4.75 | 4.75 | 0.86 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |